Financial News

Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 23rd Annual Global Healthcare Conference, being held September 8-10 in New York, New York. Dr. Bigal will be presenting on September 8th at 1:50 p.m. ET.

About Ventus Therapeutics

Ventus Therapeutics is a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE®, the company has established a robust pipeline, including three wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor in Phase 2 for lupus. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson’s disease, and is expected to commence a Phase 2 trial for osteoarthritis in obese patients later in 2025. VENT-04 is a first-in-class caspase-4/5 inhibitor in preclinical development. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.75
-8.91 (-3.34%)
AAPL  352.78
-3.49 (-0.98%)
AMD  504.28
-29.78 (-5.58%)
BAC  50.08
-0.94 (-1.84%)
GOOG  281.26
-11.26 (-3.85%)
META  626.41
-15.28 (-2.38%)
MSFT  517.99
-5.89 (-1.12%)
NVDA  156.14
-6.71 (-4.12%)
ORCL  119.09
-6.26 (-4.99%)
TSLA  379.74
-10.48 (-2.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback